Compare ADMA Biologics Inc (ADMA) vs American Electric Power Company Inc (AEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs American Electric Power Company Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while American Electric Power Company Inc trades at $123.7 (market cap $66.87B). The key difference: American Electric Power Company Inc is far larger — about 30.7× ADMA Biologics Inc's market cap, and American Electric Power Company Inc pays a 3.09% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AEP | |
|---|---|---|
Market Cap | $2.18B | $66.87B |
Sector | Health | Utilities |
52-Week High | $20.38 | $138.69 |
52-Week Low | $7.60 | $106.44 |
Enterprise Value | $2.25B | $119.77B |
Dividend Yield | — | 3.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
American Electric Power (AEP) trades at $125.73, up 0.38% on the day, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings missed estimates at $1.36 per share versus $1.48 expected, though the company raised full-year 2026 operating EPS guidance to $6.25–$6.55, reflecting confidence in AI-driven power demand growth. Fundamentals show robust revenue growth to $21.88B in 2025 and a net income margin of 13.78%, supported by a $78 billion capital plan.
The outlook remains positive due to contracted load growth and infrastructure investments, but risks include execution of large capital expenditures and interest rate sensitivity. With a consensus price target of $140.89 and no sell ratings, Wall Street sentiment is bullish, though technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →
